文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺SBRT推量后急性、亚急性与晚期泌尿系统生活质量的相关性

Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost?
PubMed 文献 · Radiother Oncol · 2026-06-19

本研究为PROMETHEUS前瞻性II期试验的事后分析,纳入151例接受SBRT作为虚拟高剂量率近距离放疗推量的前列腺癌患者,中位随访60个月。采用EPIC-26评分和最小临床重要差异(MCID)分析发现,晚期尿失禁MCID与治疗结束时及12个月MCID、既往TURP和Rectafix相比SpaceOAR相关;晚期刺激症状MCID与基线刺激功能差和亚急性刺激相关;晚期梗阻症状MCID无关联。

要点

  • 晚期尿失禁与治疗结束及12个月时尿失禁MCID、既往TURP、Rectafix相比SpaceOAR相关。
  • 晚期刺激症状与基线刺激功能差及亚急性刺激症状相关。
  • 晚期梗阻症状MCID未发现与急性或亚急性症状相关。

核心结论

  • 前列腺SBRT推量后存在经历急性、亚急性和晚期泌尿系统毒性的患者亚群。
  • 基线或亚急性刺激症状是长期刺激症状的预测因素。
  • 既往TURP或基线刺激症状患者可能从密切评估和随访干预中获益。

研究设计与样本

  • PROMETHEUS前瞻性II期试验(ACTRN12615000223538)的事后分析。
  • 纳入151例接受SBRT作为虚拟高剂量率近距离放疗推量的前列腺癌患者,中位随访60个月。
  • 使用EPIC-26评分和最小临床重要差异(MCID)评估急性(治疗结束时)、亚急性(12个月)和晚期(36和60个月)泌尿系统生活质量变化。
  • 分别对尿失禁、梗阻和刺激域进行单变量和多变量逻辑回归分析。

主要发现

  • 多变量分析显示,晚期尿失禁MCID与治疗结束时MCID相关(OR 3.55 [95% CI 1.42-8.92],p=0.01)和12个月MCID相关(OR 8.72 [95% CI 3.53-21.56],p<0.01)。
  • 既往TURP(OR 6.11 [95% CI 1.56-23.89],p=0.01)和Rectafix相比SpaceOAR(OR 2.6 [95% CI 1.09-6.23],p=0.03)也与晚期尿失禁相关。
  • 晚期刺激症状MCID与基线刺激功能差相关(OR 7.95 [95% CI 1.71-36.91],p<0.01)和亚急性刺激相关(OR 5.47 [95% CI 2.11-14.18],p<0.01)。
  • 未发现与晚期梗阻症状MCID相关的因素。

关键数值与推荐

  • 晚期尿失禁MCID与治疗结束时MCID:OR 3.55(95% CI 1.42-8.92),p=0.01。
  • 晚期尿失禁MCID与12个月MCID:OR 8.72(95% CI 3.53-21.56),p<0.01。
  • 晚期尿失禁MCID与既往TURP:OR 6.11(95% CI 1.56-23.89),p=0.01。
  • 晚期尿失禁MCID与Rectafix相比SpaceOAR:OR 2.6(95% CI 1.09-6.23),p=0.03。
  • 晚期刺激症状MCID与基线刺激功能差:OR 7.95(95% CI 1.71-36.91),p<0.01;与亚急性刺激:OR 5.47(95% CI 2.11-14.18),p<0.01。

临床怎么用

  • 对既往TURP或基线刺激症状的前列腺SBRT患者,随访期间应密切评估和干预。
  • 治疗结束时和12个月泌尿系统生活质量变化可能提示晚期尿失禁风险。

局限性

  • 本文为事后分析,未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Emerging evidence demonstrates an association between acute and late genitourinary (GU) toxicity following prostate radiotherapy. However, this is not established following SBRT, and subacute toxicities may represent a transient and independent entity. We conducted a post-hoc analysis of the PROMETHEUS prospective phase II trial (ACTRN12615000223538) to investigate correlations among acute, subacute, and late GU QOL in patients who received SBRT as a virtual-high-dose-rate brachytherapy boost for prostate cancer. METHODS: The trial consisted of 151 men, with a median follow-up of 60 months. Relationships between acute (end of treatment [EOT]), subacute (12 months), and late (36 and 60 months) GU QOL changes were examined using EPIC-26 scores and minimal clinically important differences (MCID). Univariable and multivariable logistic regression were performed separately for incontinence, obstructive, and irritative domains. KEY FINDINGS: On multivariable analysis, late incontinence MCID was associated with MCID at EOT (OR 3.55 [95% CI 1.42-8.92], p = 0.01) and 12 M (8.72 [3.53-21.56], p < 0.01). Prior TURP (6.11 [1.56-23.89], p = 0.01) and Rectafix versus SpaceOAR (2.6 [1.09-6.23], p = 0.03) were also associated with late incontinence. Late irritative MCID was associated with poor baseline irritative function (7.95 [1.71-36.91], p < 0.01) and subacute irritation (5.47 [2.11-14.18], p < 0.01). No associations were identified with late obstructive MCID. CONCLUSIONS: This study identifies subsets of men who experience acute, subacute and late GU toxicity after prostate SBRT. Baseline or subacute irritative symptoms are predictors of longer-term irritation. Patients with prior TURP or baseline irritative symptoms may benefit from close assessment and intervention during follow-up.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chan L, Martin J, Sidhom M, et al. Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost? Radiother Oncol. 2026. PMID: 42320679. doi:10.1016/j.radonc.2026.111650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。